Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue
Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease....
Saved in:
Main Authors: | Sofia Dias, Sílvia Paredes, Laura Ribeiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/2637418 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Visceral Adipose Tissue Inflammation and Vascular Complications in a Rat Model with Severe Dyslipidemia: Sex Differences and PAI-1 Tissue Involvement
by: Irena Markova, et al.
Published: (2024-12-01) -
Abdominal Obesity, Dyslipidemia and Blood Pressure
by: Pedro Enrique Miguel Soca
Published: (2015-11-01) -
The Role of Adipose Tissue and Adipokines in Obesity-Related Inflammatory Diseases
by: Carmela Rita Balistreri, et al.
Published: (2010-01-01) -
Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children
by: Asma Deeb, et al.
Published: (2018-01-01) -
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
by: Almudena Gómez-Hernández, et al.
Published: (2016-01-01)